Logo

Sagres, Genome Institute of Singapore in Cancer Research Collaboration

Sep 16, 2003

NEW YORK, Sept. 16 (GenomeWeb News) - Sagres Discovery today said it has signed a cancer research collaboration with the Genome Institute of Singapore (GIS).

GIS will use gene-expression profiling and bioinformatics to characterize a collection of Sagres' proprietary provirus-tagged mouse tumors. GIS and Sagres said they would compare the gene-expression data with expression profiles of human cancers in order to map the genetic interaction pathways of the Oncogenome - a list of cancer-causing genes that Sagres has identified.

Sagres said it would have the option to obtain from GIS exclusive rights to novel genes and pathways identified during the collaboration, with commercial terms to be agreed separately. GIS will retain the right to use the results for its non-commercial research and development.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.